This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Northwest Bio: Interim Analysis of Brain Cancer Vaccine Study Past Due

By: Adam Feuerstein | 03/03/14 - 10:32 AM EST

Stocks in this article: NWBOIMUCCLDX

Northwest Biotherapeutics (NWBO) is way overdue disclosing results from an interim analysis of a phase III study of its brain cancer vaccine DCVax.

Twelve weeks have passed since Northwest Bio said independent data monitors were taking their first look at the study, which compares DCVax to placebo in patients with newly diagnosed glioblastoma mutliformae (GBM).

Results from the interim analysis were expected no later than the first week of February, Northwest Bio said. On Feb. 10, Northwest Bio CEO Linda Powers, speaking at the BIO CEO healthcare investor conference, said data monitors needed "another couple of weeks" to complete their work.

We're now another week beyond Power's acknowledged delay and still no word from the company.

Last March -- almost one year ago, actually -- Northwest Bio told investors enrollment in the 312-patient GBM study of DCVax would be completed this quarter or early in the second quarter, and that the first interim analysis would be conducted in the third quarter of 2013.

Northwest Bio spokesperson Farrell Kramer would not disclose the current number of GBM patients enrolled in the DCVax study. "We're not at liberty to provide any information to you that has not been announced publicly," Kramer said, via email.

The DCVax study in GBM has gone through numerous design changes and patient enrollment freezes since it was started in 2005 as a small, non-randomized phase II study expected to enroll 90 patients. In addition to upsizing to 312 newly diagnosed GBM patients, Northwest Bio added a placebo arm to the study and changed its designation to "phase III" -- implying positive results could be used to support an FDA approval filing.

Northwest Bio claims FDA agreed to the changes made the DCVax study but the company does not have a Special Protocol Assessment (SPA) agreement with regulators.

The lack of an SPA is a real concern because Northwest is using a primary endpoint for the DCVAx study -- progression-free survival -- which appears to fall short of FDA's approval standards for therapies addressing newly diagnosed GBM patients.

ImmunoCellular Therapeutics (IMUC) used overall survival as the primary endpoint for a recently completed phase II study of its brain cancer vaccine ICT-107 based on feedback from the FDA.

In a recent shareholder letter, ImmunoCellular stated:

We selected OS as the primary endpoint for clear, pragmatic reasons: to follow the guidance of the FDA relative to what constitutes a registration endpoint, and to inform the design of a phase III registration study. In 2011 written correspondence with our Company regarding our phase II protocol, the FDA indicated "progression free survival (PFS) as an endpoint is acceptable for hypothesis testing, but not as a primary endpoint for a phase 3 trial to support a BLA." Based on FDA's guidance, we focused the trial on generating detailed survival data, and retained PFS as an important secondary clinical endpoint.

Celldex Therapeutics (CLDX) is also using overall survival as the primary endpoint for an ongoing phase III study of its brain cancer vaccine rindopepimut.

Northwest Bio has never explained why FDA would agree to review DCVax for approval based on progression-free survival data when two other companies also developing vaccines for newly diagnosed GBM patients said FDA wanted overall survival as the primary endpoint.

The efficacy bar for any interim analysis is always set high, so an announcement from Northwest Bio that the DCVax GBM study is continuing is the most likely outcome of the first interim analysis. However, Northwest Bio should also update investors on the pace of overall enrollment and better explain why a study long-delayed, changed and utilizing a non-approvable primary endpoint can be considered registration worthy. 


Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Markets

DOW 16,700.16 +238.84 1.45%
S&P 500 1,953.36 +26.25 1.36%
NASDAQ 4,456.4650 +73.6180 1.68%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs